<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21248" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Epinephrine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dalal</surname>
            <given-names>Rajeev</given-names>
          </name>
          <aff>Penn State Health Milton S. Hershey Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Grujic</surname>
            <given-names>Dejan</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rajeev Dalal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dejan Grujic declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21248.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Epinephrine is one of the most commonly used agents in various settings as it functions as medication and hormone. It is currently FDA-approved for various situations, including emergency treatment of type 1 hypersensitivity reactions, including anaphylaxis, induction, and maintenance of mydriasis during intraocular surgeries and hypotension due to septic shock. It also has several off-label uses. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of epinephrine, pertinent for members of the interprofessional team in treating patients with conditions where this agent is indicated.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the various indications for epinephrine.</p></list-item><list-item><p>Review the mechanism of action of epinephrine.</p></list-item><list-item><p>Identify the potential adverse events associated with epinephrine.</p></list-item><list-item><p>Summarize the importance of interprofessional communication, improving care coordination among the interprofessional team when initiating epinephrine therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21248&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21248">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21248.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Epinephrine is one of the most commonly used agents in various settings as it functions as medication and hormone. It is currently FDA-approved for&#x000a0;various situations, including emergency treatment of type 1 hypersensitivity reactions, including anaphylaxis, induction, and maintenance of mydriasis during intraocular surgeries and hypotension due to septic shock.<xref ref-type="bibr" rid="article-21248.r1">[1]</xref> Off-label uses of epinephrine include, but are not limited to, ventricular fibrillation, pulseless ventricular tachycardia, asystole, pulseless electrical activity (PEA), croup, and severe asthma exacerbations unresponsive to standard treatment.<xref ref-type="bibr" rid="article-21248.r2">[2]</xref><xref ref-type="bibr" rid="article-21248.r3">[3]</xref> In the operating room (OR) setting, epinephrine is also used as a local anesthetic block. Produced by the adrenal medulla, epinephrine plays a vital role in the body&#x02019;s acute stress response by stimulating the sympathetic nervous system.<xref ref-type="bibr" rid="article-21248.r4">[4]</xref></p>
      </sec>
      <sec id="article-21248.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Epinephrine is a sympathomimetic catecholamine that exerts its pharmacologic effects on both alpha&#x000a0;and beta-adrenergic receptors using a G protein-linked second messenger system. It has a greater affinity for beta receptors in small doses. However, large doses produce selective action on alpha receptors. Through its action on alpha-1 receptors, epinephrine induces increased vascular smooth muscle contraction, pupillary dilator muscle contraction, and intestinal sphincter muscle contraction. Other significant effects include increased heart rate, myocardial contractility, and renin release via beta-1 receptors. Beta-2 effects produce bronchodilation, which may be useful as an adjunct treatment of asthma exacerbations and vasodilation, tocolysis, and increased aqueous humor production.</p>
      </sec>
      <sec id="article-21248.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Depending on the diagnosis, epinephrine administration can be in various forms. For the treatment of anaphylaxis, epinephrine is preferably injected intramuscularly into the anterolateral aspect of the thigh due to rapid absorption. Subcutaneous&#x000a0;injection is also an option. For advanced cardiovascular life support (ACLS), patients can receive epinephrine intravenously or intraosseous if needed. Another route of administration is through an endotracheal tube often used in neonatal resuscitation.</p>
      </sec>
      <sec id="article-21248.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Effects Listed by System</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Central nervous system (CNS): Anxiety, dizziness, nervousness, agitation, headache, Parkinson disease exacerbation</p>
          </list-item>
          <list-item>
            <p>Cardiovascular: Arrhythmias, chest pain, hypertension, palpitations, tachycardia, cerebrovascular accidents, ventricular ectopy, vasospasm, tissue ischemia</p>
          </list-item>
          <list-item>
            <p>Dermatologic: Gangrene at the injection site (especially in buttocks), skin necrosis with extravasation</p>
          </list-item>
          <list-item>
            <p>Endocrine: Hyperglycemia, hypokalemia, lactic acidosis</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal: Nausea, vomiting, increase in AST and ALT</p>
          </list-item>
          <list-item>
            <p>Neuromuscular: Tremors, weakness</p>
          </list-item>
          <list-item>
            <p>Renal: Decreased renal perfusion</p>
          </list-item>
          <list-item>
            <p>Respiratory: Dyspnea, pulmonary edema</p>
          </list-item>
        </list>
        <p>The more common side effects include tachycardia, hypertension, headache, anxiety, apprehension, palpitations, diaphoresis, nausea, vomiting, weakness, and tremors.</p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Alpha-adrenergic blockers: Antagonizes pressor effects</p>
          </list-item>
          <list-item>
            <p>Antihypertensives: Antagonizes pressor effects</p>
          </list-item>
          <list-item>
            <p>Vasodilators: Antagonizes pressor effects</p>
          </list-item>
          <list-item>
            <p>Diuretics: Antagonizes pressor effects</p>
          </list-item>
          <list-item>
            <p>Beta-adrenergic blockers: Potentiates pressor effects</p>
          </list-item>
          <list-item>
            <p>Monoamine oxidase (MAO) inhibitors: Potentiates pressor effects</p>
          </list-item>
          <list-item>
            <p>Catechol-o-methyltransferase (COMT) inhibitors: Potentiates pressor effects</p>
          </list-item>
        </list>
        <p>Careful monitoring of vital signs is crucial, especially in patients with polypharmacy.</p>
      </sec>
      <sec id="article-21248.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are no absolute contraindications against using epinephrine. Some relative contraindications include hypersensitivity to sympathomimetic drugs, closed-angle glaucoma, anesthesia with halothane. Another unique contraindication to be aware of is catecholaminergic polymorphic ventricular tachycardia.<xref ref-type="bibr" rid="article-21248.r5">[5]</xref> As is the case with prescribing any medication, all practitioners should use clinical judgment and evaluate the benefits versus risks with epinephrine.</p>
        <p>Select circumstances indicate the need for additional assessment before using epinephrine, as discussed below.</p>
        <p>
<bold>Pregnancy</bold>
</p>
        <p>Epinephrine is considered a pregnancy Category C medication under the old FDA categorization system. There are no well-controlled studies in humans, although animal studies have shown a teratogenic risk during organogenesis. It is capable of crossing the placenta. Epinephrine use requires caution when maternal blood pressure is 130/80 mm Hg and greater.</p>
        <p>
<bold>Labor and Delivery</bold>
</p>
        <p>Due to its effect on beta-2 adrenergic receptors causing tocolysis, epinephrine opposes the actions of oxytocin on the uterus and may delay labor. It also requires caution during anaphylaxis-induced hypotension in pregnancy as it may lead to uterine vasoconstriction, thus decreasing oxygen delivery to the fetus.<xref ref-type="bibr" rid="article-21248.r6">[6]</xref></p>
        <p>
<bold>Breastfeeding</bold>
</p>
        <p>More clinical studies are needed to determine if epinephrine is excreted through breast milk.</p>
        <p>
<bold>Pediatrics</bold>
</p>
        <p>Epinephrine is effective at a dilution of between 1 to 100,000 and 1 to 400,000 for mydriasis induction and maintenance in pediatric intraocular surgeries.</p>
        <p>
<bold>Geriatrics</bold>
</p>
        <p>Due to the expected decrease in renal, hepatic, and cardiac function of geriatric patients, epinephrine should be started at the lower end of the dosing regime and titrated appropriately for clinical effect.</p>
        <p>
<bold>Location</bold>
</p>
        <p>Several locations should be avoided when injecting epinephrine, specifically the digits, nose, penis, and toes, as these areas are more prone to ischemia. Avoid using epinephrine in tissues supplied by end arteries.</p>
      </sec>
      <sec id="article-21248.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>When administered parenterally, epinephrine has a rapid onset but a short duration of action. When given intravenously, it has a half-life of fewer than 5 minutes. Metabolism is primarily in the liver, along with various other locations such as the kidneys, skeletal muscle, and mesenteric organs. It is degraded into an inactive metabolite named vanillylmandelic acid by MAO and COMT and excreted into the urine. However, a small amount of the drug is excreted unchanged as well.</p>
        <p>Epinephrine is a hormone that produces widespread effects. Certain effects need monitoring. Tachycardia and hypertension are expected effects when giving epinephrine intravenously, so it is important to titrate the drug carefully while monitoring hemodynamics. Epinephrine is also used with anesthetic agents to provide analgesia. In locations where extravasation of epinephrine has occurred, prevention and treatment of ischemia-induced necrosis are necessary. The infiltrated area should receive treatment with a 10 mL to 15 mL saline solution containing 5 mL to 10 mg of phentolamine, an alpha-adrenergic blocking agent. A study showed how hospitalized patients in the ICU with finger ischemia were associated with the use of vasopressors, including epinephrine.<xref ref-type="bibr" rid="article-21248.r7">[7]</xref></p>
        <p>Renal impairment requires monitoring as epinephrine causes renal blood vessel constriction and can decrease urine impairment. In patients with chronic kidney disease (CKD) and various other renal pathologies, clinical judgment is necessary. Researchers discovered a new enzyme named renalase produced by the kidneys and responsible for metabolizing epinephrine. Some studies have shown how renalase is deficient in CKD, making epinephrine levels greater in CKD.&#x000a0;<xref ref-type="bibr" rid="article-21248.r8">[8]</xref>&#x000a0;During intraocular use, epinephrine requires dilution; otherwise, corneal endothelial damage can result from the administration of undiluted concentrations of sodium bisulfite.</p>
      </sec>
      <sec id="article-21248.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Administration of excess epinephrine that leads to supra-therapeutic levels may cause predictable adverse effects that warrant supportive treatment. Overdose may cause elevated arterial pressures leading to cerebrovascular accidents. Pressor effects can be minimized by using an alpha-adrenergic blocker or by the usage of vasodilators such as nitrites. Pulmonary edema can also present due to the underlying mechanism of peripheral vasoconstriction along with myocardial stimulation.<xref ref-type="bibr" rid="article-21248.r9">[9]</xref> Respiratory support may be needed alongside an alpha-adrenergic blocking drug to decrease vasoconstriction and enhance vascular flow. Due to strong beta-1 adrenergic effects on cardiac tissue, epinephrine toxicity may lead to potentially fatal cardiac arrhythmias or ischemia. Treatment involves the administration of beta-adrenergic blocking agents such as metoprolol.</p>
      </sec>
      <sec id="article-21248.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>With numerous medications readily available for a variety of medical conditions for inpatient and outpatient settings, epinephrine is not often&#x000a0;a topic of discussion until a patient exhibits severe medical deterioration. Because of its physiologic effects, epinephrine is a common agent used in "code" situations, including ventricular fibrillation and PEA. These situations require the expertise and skills of the entire interprofessional healthcare team comprised of physicians, nurses, pharmacists, EMTs, and other health professionals. During these circumstances, there is a team leader, usually&#x000a0;an attending clinician, who oversees and makes medical decisions for the patient. The clinician, along with the help of other healthcare professionals and students, interprets EKGs and indicates if and when epinephrine&#x000a0;is required.&#x000a0;From an emergency medical technician&#x000a0;standpoint in prehospital settings, epinephrine comes already prepared for&#x000a0;administration,&#x000a0;versus other&#x000a0;hospital settings where the person administering the drug must draw it with a syringe. Interprofessional communication is vital during these times, so all healthcare professionals are aware of the necessary steps required to resuscitate the patient.</p>
        <p>The proper dosage of medication must be administered within an&#x000a0;appropriate period to limit the risk of toxicity; thus, there should be a pharmaceutical consult on these cases. Communication among all team members must be fluid, as all members function as an interprofessional team, not as individuals operating in silos of expertise. Researchers recently conducted a randomized, double-blinded trial in the United Kingdom whose primary endpoint was to examine the survival rate at thirty days of out-of-hospital cardiac arrests, with secondary outcomes to study the rate of survival until hospital discharge with favorable neurologic outcome. The study included more than 8,000 patients; roughly half were given parenteral epinephrine or saline placebo, with appropriate standard care. The conclusion was that there was a higher thirty-day survival with epinephrine as opposed to saline placebo. However, there was no improvement in neurologic outcome.<xref ref-type="bibr" rid="article-21248.r10">[10]</xref></p>
        <p>Interprofessional management of epinephrine therapy will yield the best patient outcomes with the fewest adverse effects. [Level 5]</p>
      </sec>
      <sec id="article-21248.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21248&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21248">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21248/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21248">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21248.s11">
        <title>References</title>
        <ref id="article-21248.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacha</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lat</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Vasoactive Agent Use in Septic Shock: Beyond First-Line Recommendations.</article-title>
            <source>Pharmacotherapy</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>369</fpage>
            <page-range>369-381</page-range>
            <pub-id pub-id-type="pmid">30644586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21248.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goodall</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Guideline review: Epinephrine use in anaphylaxis (AAP guideline 2017).</article-title>
            <source>Arch Dis Child Educ Pract Ed</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>105</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-40</page-range>
            <pub-id pub-id-type="pmid">30442676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21248.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Kwak</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Paek</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of low-dose nebulized epinephrine as treatment for croup: A randomized, placebo-controlled, double-blind trial.</article-title>
            <source>Am J Emerg Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>12</issue>
            <fpage>2171</fpage>
            <page-range>2171-2176</page-range>
            <pub-id pub-id-type="pmid">30878411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21248.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lyng</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>TQ</given-names>
              </name>
              <name>
                <surname>Lako-Adamson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goodloe</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dailey</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Clemency</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Non-Auto-Injector Epinephrine Administration by Basic Life Support Providers: A Literature Review and Consensus Process.</article-title>
            <source>Prehosp Emerg Care</source>
            <year>2019</year>
            <season>Nov-Dec</season>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>855</fpage>
            <page-range>855-861</page-range>
            <pub-id pub-id-type="pmid">30917719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21248.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bellamy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nuthall</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dalziel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Catecholaminergic Polymorphic Ventricular Tachycardia: The Cardiac Arrest Where Epinephrine Is Contraindicated.</article-title>
            <source>Pediatr Crit Care Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>262</fpage>
            <page-range>262-268</page-range>
            <pub-id pub-id-type="pmid">30640888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21248.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeon</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Maternal anaphylactic shock in pregnancy: A case report.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>97</volume>
            <issue>37</issue>
            <fpage>e12351</fpage>
            <pub-id pub-id-type="pmid">30212990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21248.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landry</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Mostul</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>McLafferty</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Liem</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>CZ</given-names>
              </name>
              <name>
                <surname>Azarbal</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>McLafferty</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Moneta</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Causes and outcomes of finger ischemia in hospitalized patients in the intensive care unit.</article-title>
            <source>J Vasc Surg</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>1499</fpage>
            <page-range>1499-1504</page-range>
            <pub-id pub-id-type="pmid">29685512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21248.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rezk</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Zidan</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Elnaggar</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Ghorab</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Renalase gene polymorphism and epinephrine level in chronic kidney disease.</article-title>
            <source>Appl Biochem Biotechnol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>175</volume>
            <issue>4</issue>
            <fpage>2309</fpage>
            <page-range>2309-17</page-range>
            <pub-id pub-id-type="pmid">25484193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21248.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x000fc;nser</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Hasibeder</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress.</article-title>
            <source>J Intensive Care Med</source>
            <year>2009</year>
            <season>Sep-Oct</season>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>293</fpage>
            <page-range>293-316</page-range>
            <pub-id pub-id-type="pmid">19703817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21248.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perkins</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Deakin</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Scomparin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Regan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Slowther</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>JJM</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fothergill</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>O'Shea</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Docherty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gunson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Charlton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Petrou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stallard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gates</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lall</surname>
                <given-names>R</given-names>
              </name>
              <collab>PARAMEDIC2 Collaborators</collab>
            </person-group>
            <article-title>A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Aug</month>
            <day>23</day>
            <volume>379</volume>
            <issue>8</issue>
            <fpage>711</fpage>
            <page-range>711-721</page-range>
            <pub-id pub-id-type="pmid">30021076</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
